Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
about
Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal womenAdjuvant Gonadotropin-releasing hormone analogues for chemotherapy induced premature ovarian failure in premenopausal womenCurrent and emerging pharmacological treatments for sarcoidosis: a reviewAnti-inflammatory and immunosuppressive drugs and reproductionFertility preservation treatment for young women with autoimmune diseases facing treatment with gonadotoxic agents.Fertility and pregnancy in rheumatoid arthritis and systemic lupus erythematosus.Rheumatic autoimmune diseases in women and midlife healthOvarian preservation by GnRH agonists during chemotherapy: a meta-analysis.High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trialSafety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis.Variability of the impact of adverse events on physicians' decision makingHyaluronic acid prevents immunosuppressive drug-induced ovarian damage via up-regulating PGRMC1 expression.Wegener granulomatosisNonmalignant diseases and treatments associated with primary ovarian failure: an expanded role for fertility preservation.Randomized, double-blind, dose-escalation trial of triptorelin for ovary protection in childhood-onset systemic lupus erythematosus.Treating rheumatic diseases in pregnancy: dos and don'tsFemale long-term survivors after allogeneic hematopoietic stem cell transplantation: evaluation and management.Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritisNotes on the kidney and its diseases for the neurologist.Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelinesSystemic lupus erythematosus: current state of diagnosis and treatment.Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus.Ovarian recovery after stem cell transplantation.Pregnancy and autoimmune connective tissue diseasesOvarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility.GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy.Oral cyclophosphamide for lupus glomerulonephritis: an underused therapeutic option.Breast cancer and fertility preservationManagement of systemic lupus erythematosus in Chinese patients.Medical approaches to preservation of fertility in female cancer patients.Pediatric SLE--towards a comprehensive management plan.Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis.Prevention of ovarian damage and infertility in young female cancer patients awaiting chemotherapy--clinical approach and unsolved issues.Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network.Fertility preservation in patients receiving cyclophosphamide therapy for renal disease.Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists.The safety of pharmacological treatment options for lupus nephritis.Infertility - Prevention and Management.Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study.
P2860
Q24235150-706082D3-2AB3-4CCD-A639-4238C92421ACQ24241143-CF54B5BA-0AFB-4DDB-B5B2-1174FE4D0899Q24633717-722FC223-6E32-4A1F-8312-3111472F9E44Q28218219-AFD6E49E-372E-4330-B580-143E616D9BC5Q33380516-FAACFC97-B9C4-4D5F-B5C8-6727F19A68EBQ33654712-050C3F71-86AF-402B-BD77-F807767B93C4Q33727015-FB4C1A4D-7C46-49C4-88C5-3C9404DF2E0EQ33805271-CF3E0AF3-4533-410D-B1B4-4B73B1D69BBBQ34027812-44B47562-E1F8-4FA3-B6F8-E62E8BE81B54Q34066226-538813B3-03E3-48B7-83A4-E82D0543B14CQ34538062-12772DF6-2490-4BED-B9AF-0584A660AA50Q34830224-94E9E0BA-0472-4185-9A2F-59F2CCDC43AEQ35103662-E89040E4-78C7-44C1-80DD-24AFFB2294FEQ35267073-DB84E8FB-63F6-4F17-8E97-6C52704429CDQ35554367-3511B725-26F4-4952-9F10-4FD8E6101E98Q35638239-1DE384A3-A69D-46DC-BD62-E0C069043BA9Q35671371-61213001-5889-4372-96A6-D0A8AB0974BEQ36094947-5272905C-6691-4046-AC45-B1DF58137139Q36221407-FF0C5912-FD13-4256-8DDC-ABD2537A2D73Q36227382-0BBDB550-86C2-4A4E-A537-4D5695375C14Q36724093-F2B8346F-6BD1-44FC-A3D8-0CF9E3F32475Q36792304-0F2D44FF-1946-4E2D-BF45-98FA989F6929Q36915646-2E99C4B9-6889-4955-A8E5-444A18B9860CQ36977555-43E36471-0DAC-4A07-B8F0-367C719293EAQ37100267-4A2C68DC-2B5E-4DE3-95D0-3B4C61F639E8Q37105605-39F01BF0-F32A-4953-B82C-4F05CC27B152Q37282095-3C802DAE-98E0-4863-BDDE-71E7DAAE5B4EQ37415711-32413088-20BB-4E8F-BD40-8CC9C6161DD7Q37612074-1C4F3651-AD2B-43B0-81D0-19C68D8522EDQ37754815-F796AB19-3C0A-48EC-AF54-30A4A0E36C52Q37831349-BF86B8E5-5AC5-40F4-B5B5-CEDA6DCECB13Q37850999-5DCAF7E3-125B-4A2D-B6E3-7F02F44D0FC9Q37859113-1CA165A6-238F-40D0-8323-69B8D8012E92Q37938748-D61DD3C1-648E-42E9-877A-B02B243581E6Q37995966-C90D264E-31BC-4B69-8230-379038A052A6Q38246219-1FA8455B-6DCB-45AD-85EA-8E0330C13DD0Q38397291-7E2E3F1E-0D42-4104-9677-07852B5E9B1AQ38829637-4D15EF4B-889F-47F4-B9CA-85075D23331FQ39228582-507BD84C-626C-4D82-B2BB-7458DABC3EB1Q40183545-A07DD21C-F9FC-4686-840B-422C04893FB0
P2860
Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@en
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@nl
type
label
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@en
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@nl
prefLabel
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@en
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@nl
P2093
P356
P1476
Use of a gonadotropin-releasin ...... py in women with severe lupus.
@en
P2093
Gregory M Christman
Vladimir Ognenovski
W Joseph McCune
Wendy Marder
P304
P356
10.1002/ART.21263
P50
P577
2005-09-01T00:00:00Z